Bold Therapeutics Inc.



Suite 500 – 666 Burrard St

Vancouver BC V6C 2P6 Canada

Member Sector: Biopharmaceuticals

Bold Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies.

Bold Therapeutics’ lead asset, BOLD-100, is a first-in-class therapy for the treatment of gastric, pancreatic and other cancers that targets a novel resistance, survival and proliferation pathway common across cancers. In preclinical studies, BOLD-100 significantly enhanced the efficacy of a wide variety of anti-cancer therapies and reduced metastasis in established animal models. BOLD-100 was previously granted an Orphan Drug Designation (ODD) in the treatment of pancreatic cancer. Bold Therapeutics expects to initiate various Phase 1/2 studies of BOLD-100 in combination with existing anti-cancer therapies in 2H19.